Literature DB >> 1507232

Selection of phage antibodies by binding affinity. Mimicking affinity maturation.

R E Hawkins1, S J Russell, G Winter.   

Abstract

We describe a process, based on display of antibodies on the surface of filamentous bacteriophage, for selecting antibodies either by their affinity for antigen or by their kinetics of dissociation (off-rate) from antigen. For affinity selection, phage are mixed with small amounts of soluble biotinylated antigen (less than 1 microgram) such that the antigen is in excess over phage but with the concentration of antigen lower than the dissociation constant (Kd) of the antibody. Those phage bound to antigen are then selected using streptavidin-coated paramagnetic beads. The process can distinguish between antibodies with closely related affinities. For off-rate selection, antibodies are preloaded with biotinylated antigen and diluted into excess unlabelled antigen for variable times prior to capture on streptavidin-coated paramagnetic beads. To mimic the affinity maturation process of the immune system, we introduced random mutations into the antibody genes in vitro using an error-prone polymerase, and used affinity selection to isolate mutants with improved affinity. Starting with a small library (40,000 clones) of mutants (average 1.7 base changes per VH gene) of the mouse antibody B1.8, and using several rounds of affinity selection, we isolated a mutant with a fourfold improved affinity to the hapten 4-hydroxy-5-iodo-3-nitrophenacetyl-(NIP)-caproic acid (mutant Kd = 9.4(+/- 0.3) nM compared with B1.8 Kd = 41.9(+/- 1.6) nm). The relative increase in affinity of the mutant is comparable to the increase seen in the anti-4-hydroxy-3-nitrophenylacetyl/NIP-caproic acid murine secondary immune response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1507232     DOI: 10.1016/0022-2836(92)90639-2

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  93 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  A hierarchical approach to protein molecular evolution.

Authors:  L D Bogarad; M W Deem
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Breaking the affinity ceiling for antibodies and T cell receptors.

Authors:  J Foote; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Designer proteins in biotechnology. International Titisee Conference on protein design at the crossroads of biotechnology, chemistry and evolution.

Authors:  Hauke Lilie
Journal:  EMBO Rep       Date:  2003-03-14       Impact factor: 8.807

Review 5.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

6.  Multiplexed sorting of libraries on libraries: a novel method for empirical protein design by affinity-driven phage enrichment on synthetic peptide arrays.

Authors:  Claus Hultschig; Ronald Frank
Journal:  Mol Divers       Date:  2004       Impact factor: 2.943

Review 7.  Adapting antibodies for clinical use.

Authors:  R E Hawkins; M B Llewelyn; S J Russell
Journal:  BMJ       Date:  1992-11-28

8.  Expression of high-affinity human antibody fragments in bacteria.

Authors:  Romain Rouet; David Lowe; Kip Dudgeon; Brendan Roome; Peter Schofield; David Langley; John Andrews; Peter Whitfeld; Lutz Jermutus; Daniel Christ
Journal:  Nat Protoc       Date:  2012-02-02       Impact factor: 13.491

9.  Application of protein engineering to enhance crystallizability and improve crystal properties.

Authors:  Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-04-21

10.  A novel strategy for proteome-wide ligand screening using cross-linked phage matrices.

Authors:  Chen Qian; Jian-Ning Liu; Fengyuan Tang; Dawen Yuan; Zhigang Guo; Jing Zhang
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.